CoChat

Skeletal involvement in adult patients with endogenous hypercortisolism

Chiodini, I., Torlontano, M., Carnevale, V., Trischitta, V., Scillitani, A. · 2008 · Journal of Endocrinological Investigation

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Overt endogenous glucocorticoid excess is a well-recognized cause of bone loss and osteoporotic fractures. Cortisol excess inhibits bone formation, increases bone resorption, impairs calcium absorption from the gut, and affects the secretion of several hormones (in particular gonadotropins and GH), cytokines, and growth factors, influencing bone metabolism. The glucocorticoid excess mainly affects trabecular bone, leading to vertebral fractures in up to 70% of patients. Osteoporotic fractures may be the presenting symptom of an otherwise silent glucocorticoid excess and can precede the diagnosis of hypercortisolism by up to 2 yr. The removal of glucocorticoid excess leads to a recovery of bone mass which is, however, often incomplete and delayed, although it reduces the risk of osteoporotic fractures. Bisphosphonate therapy has been suggested to be useful in maintaining bone mass in these patients. Subclinical hypercortisolism, a condition of impaired hypothalamic- adrenal-axis homeostasis without the classical signs and symptoms of glucocorticoid excess, is a recently defined entity, which has been shown to be associated to increased bone resorption, bone loss, and high prevalence of vertebral fractures regardless of gonadal status. However, data about the effect of this subtle glucocorticoid excess on bone are still scarce and conflicting. Moreover, it is not yet known whether removing the cause of subclinical hypercortisolism leads to a recovery of bone mass and reduces the risk of osteoporotic fractures. Finally, recent data suggest that subclinical hypercortisolism is a common and underrated finding in patients with established osteoporosis. In summary, it is crucial to evaluate the risk of osteoporosis and fractures in patients with glucocorticoid excess; on the other hand, it also seems advisable to screen for glucocorticoid excess patients with osteoporotic fractures without known secondary causes of osteoporosis.

Overview

Integrity signals

Registry

Crossref · 10.1007/bf03345601

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 69 references

Research works printed but not linked: 1

  1. Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 2005, 34: 341–56. · DOI

Cited by

Metadata

Authors
Chiodini, I., Torlontano, M., Carnevale, V., Trischitta, V., & Scillitani, A.
Affiliations
  • University of Milan (IT)
  • Casa Sollievo della Sofferenza (IT)
Corresponding author
Scillitani, A.
Venue
Journal of Endocrinological Investigation
Published
2008-03
Volume
31
Issue
3
Pages
267-276
ISSN
  • 0391-4097 (ISSN-L)
  • 1720-8386
OpenAlex
W2152174465
Cited by
78
References
69
Citations by year
2026: 2 · 2025: 1 · 2024: 5 · 2023: 2 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 3 · 2014: 6 · 2013: 6 · 2012: 5
FWCI
1.45
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Endocrinological Investigation (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
endogenous hypercortisolism, Cushing's syndrome, subclinical hypercortisolism, osteoporosis, osteoporotic fractures, bone loss, bone resorption, trabecular bone, vertebral fractures, bone metabolism, hypothalamic-pituitary-adrenal axis, bisphosphonates, fracture screening
MeSH terms
Adult, Bone Diseases, Bone Resorption, Calcium, Cushing Syndrome, Female, Gonadotropins, Humans, Intestinal Absorption, Male, Osteoporosis, Risk Factors, Biomarkers, Bone Density, Spinal Fractures, Bone Remodeling, Human Growth Hormone, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.